Last reviewed · How we verify

ESP Block with Bupivacaine

Duke University · FDA-approved active Small molecule Quality 2/100

ESP Block with Bupivacaine, marketed by Duke University, is a local anesthetic currently available in the market. The key composition patent is set to expire in 2028, providing a period of exclusivity that supports its competitive position. The primary risk is the potential increase in competition following the patent expiry.

At a glance

Generic nameESP Block with Bupivacaine
SponsorDuke University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: